Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Klein, Lloyd W.
A
V
a
L
C
I
a
s
i
p
c
a
t
s
r
s
t
t
q
p
W
H
I
A
v
g
o
E
s
6
a
p
I
a
i
t
s
q
a
t
c
d

W
L
T
(
r
i
t
l
p
r
b
i
s
a
a
b
i
r
d
b
R
I
D
a
i
t
s
p
p
l
e
a
s
(
a
p
p
l
O
*
v
A
H
a
Journal of the American College of Cardiology Vol. 49, No. 2, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.039EDITORIAL COMMENT
therosclerosis Regression,
ascular Remodeling,
nd Plaque Stabilization*
loyd W. Klein, MD, FACC
hicago and Melrose Park, Illinois
mproved characterization of the composition of plaque,
dvances in understanding the vascular biology of athero-
clerosis progression, and the development of accurate
maging techniques that allow serial determinations of
laque morphology have created the opportunity for serious
onsideration of pharmacotherapeutic strategies to reverse
therosclerosis. Recent studies by Nissen et al. (1–3) show
See page 263
hat atherosclerosis regression may be a realistic goal in
ome patients. Although the actual amount of plaque
egression and compositional change is small, there may be
ubstantial clinical benefit. Yet, the question arises: what is
he therapeutic mechanism? Is it the reduced dimension of
he plaque, the decreased atheroma burden, or the conse-
uent compositional changes that confer the clinical im-
rovement?
hat Degree of Plaque Regression
as Been Achieved by Pharmacotherapy?
n the REVERSAL (Reversal of Atherosclerosis with
ggressive Lipid Lowering) trial (1), median atheroma
olume decreased (regressed) 0.4% in the high-dose statin
roup versus progressed 2.7% in the moderate-dose group
ver an 18-month period. In the ASTEROID (A Study to
valuate the Effect of ROsuvastatin on Intravascular Ultra-
ound Derived Coronary Atheroma Burden) study (2),
3.6% of patients experienced regression and mean total
theroma volume decreased 7%, with a 1% decrease in
ercent atheroma volume, after 24 months of treatment.
ntravenous recombinant apolipoprotein A1 Milano (3)
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Rush Medical College, Chicago, Illinois; and Gottlieb MemorialA
ospital, Melrose Park, Illinois. Dr. Klein is on the Speakers’ Bureau for Pfizer, King,
nd Merck.dministered in 5 weekly infusions showed a 4.1% decrease
n total atheroma volume (p  0.001).
Whether or not the small magnitude of plaque reduction
hat is observed leads directly to the improved outcomes in
imilarly designed clinical studies (4–6) is a provocative
uestion. One possibility is that although the absolute
mount of regression achieved is small, it may be sufficient
o produce clinical benefit (7). However, the reduction in
linical events over the subsequent 1 to 2 years seems
isproportionate to simply diminishing atheroma volume by
10% (8).
hich Components of the Plaque Are Most
ikely to be Targets of Pharmacotherapy?
he lipid pool is a highly accessible target for statin therapy
8,9). Cholesterol esters can be mobilized if macrophage
everse cholesterol transport is activated (9,10). By increas-
ng cholesterol efflux, either via the reverse cholesterol
ransport pathway (9) or by conversion to high-density
ipoprotein esters via the cholesterol ester transfer protein
athway (11,12), an imbalance between the deposition and
emoval of vascular cholesterol after endothelial injury may
e corrected.
Fibrous tissue and ground substance would seem to be
rreversible despite metabolic manipulation. However,
tatins have been shown to diminish smooth muscle cell
ccumulation and collagen deposition (13). Calcification
lso seems to be a nonreversible change, but this has not
een formally evaluated. Conversely, inflammatory reaction
n the forms of cellular migration, humoral substance
elease, and edema are obviously potential targets. Statins
ecrease inflammation, an effect correlated with clinical
enefit (14–16).
egression and Stabilization:
s There a Relationship?
ecreasing endothelial injury, diminishing lipid content,
nd altering the cellular elements and inflammatory milieu
n the subendothelial layer may ameliorate the susceptibility
o plaque rupture. The targets of regression seem to be the
ame as those invoked in vulnerable plaque passivation. It is
robably not coincidental that the smaller, lipid-rich
laques that are prone to rupture are also the ones most
ikely to regress (13), nor is it accidental that clinical trials
valuating the long-term effects of intensive pharmacother-
py identify study candidates as those with acute coronary
yndromes (ACS) (3–7), or include them in large numbers
1,2).
An important consideration is that vulnerable plaque is
ssociated with positive remodeling, whereas nonvulnerable
laque undergoes negative remodeling. Plaques that show
ositive remodeling contain “soft” noncalcified plaque with
arge lipid cores and an active inflammatory process (17).
utward (or positive) remodeling is strongly associated with
CS and plaque rupture, whereas constrictive (or negative)
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Editorial Comment January 16, 2007:271–3emodeling is more common in patients with stable angina
17,18). Diminished lipid core, negative remodeling, and
mall changes in plaque size are observed in response to
ntensive lipid lowering (19). Progressors show positive
emodeling, whereas regressors show negative remodeling
20). Progression can be associated with a paradoxical
ncrease in lumen cross-sectional area, whereas regression is
ot associated with any change in lumen area, suggesting a
omplex relationship among these factors. Treatment with
tatins is associated with constrictive remodeling (21).
chartl et al. (22) found that the hyperechogenicity index
composed of dense fibrous or elastic tissue) increased in
torvastatin-treated patients, whereas calcification and hy-
oechogenic plaque (loose fibrous, lipoid, and necrotic
issue) remained constant.
In the ESTABLISH (Early Statin Treatment in Patients
ith Acute Coronary Syndrome) trial (23), early statin
reatment in patients with ACS resulted in regression of
therosclerotic lesions 6 months later. Plaque volume was
educed 13% from baseline in the atorvastatin-treated
roup, but increased 9% in the control group (p  0.03).
hese data further suggest an overlap between the concepts
f passivation and regression.
The qualities shared by drug-induced quiescence of the
otentially vulnerable plaque and regression of soft plaque
uggests that stable atheromas would be more resistant to
egression. However, because current studies exclude lesions
ith 50% luminal narrowing, whether or not high-grade
esions are less responsive to medical therapy cannot be
ddressed directly (8). Also, obstructive stenoses do remain
apable of compensatory remodeling, and have been shown
o have the potential for the greatest degree of regression
24,25). In the Stary classification (26), regression of types I
o III (early and preatheroma) to normal is possible, whereas
ecreasing lipid content in lesion types IV to VI (atheromas,
broatheromas, and complicated lesions) results in transfor-
ation to types VII to VIII (calcific and fibrotic lesions).
ew Findings
n this context, the findings of Nicholls et al. (27) in this
ssue of the Journal are extraordinarily relevant to under-
tanding the vascular response to statin and antihypertensive
herapy. The investigators re-examined the intravascular
ltrasound (IVUS) findings in the REVERSAL and NOR-
ALIZE studies (28), and determined that the more
alcified atheromas were resistant to change, either progres-
ion or regression. Conversely, less calcification was a sign of
otential for significant changes over time, either progres-
ion or regression. The findings suggest that the various
omponents of atheroma respond differently to treatment
ith medical therapies, and can be used to target plaques
hat are likely to respond. A secondary conclusion is that
maging techniques that assess clinical response to therapy
n the basis of changes in the degree of calcification may be
heoretically flawed. fAn important drawback of the study is that the investi-
ators did not analyze whether constrictive remodeling is
scribable to diminished volume of hypolucent plaque on
he IVUS. They did not describe whether the luminal
imension increased, or whether atheroma volume de-
reased because of compression or actual decreases in
theroma tissue. Because the remodeling index is calculated
t the worst single site but atheroma volume is summated in
ultiple slices, the relationship between atherosclerosis
egression and constrictive remodeling is ambiguous. It is
ntuitive that remodeling is probably one aspect of regres-
ion, but the data analysis implies that these are inseparable
rocesses. In the investigators’ defense, IVUS is not the best
maging technique for reconciling these relationships, and it
s not the most accurate method for quantifying calcification.
ow May These Observations Alter the
iagnostic and Therapeutic Approach to Patients?
f potentially vulnerable plaque is the form of atherosclerosis
ost amenable to regression, then improved imaging tech-
iques that reliably identify it are required. A better com-
rehension of where soft and vulnerable plaques are located
ithin a field of atherosclerosis is necessary to develop
maging techniques most apt to reliably find them. Then,
he natural history of these plaques must be definitively
stablished for therapeutic judgments to be made once they
re found (Table 1).
It will also be important to correlate traditional risk
actors with mechanisms of disease and potential response
o therapy. For example, male gender, diabetes, and a
istory of prior revascularization are independent predictors
f atherosclerotic burden (25). There is also an association
etween negative remodeling, calcification, and age 80
ears, suggesting that the elderly may be less responsive to
edical therapy (29).
The work of Nissen et al. sets the stage for the develop-
ent of a pharmacologic approach to producing regression
f coronary atherosclerosis. In the future, patients could be
reated acutely with intravenous infusions of various agents
o induce stabilization and regression, and then placed on
ong-term oral therapy for further improvement and main-
enance. The development of therapeutic programs of the
uestions Regarding Locationf Soft and/or Vul erable Plaques
Table 1 Questions Regarding Locationof Soft and/or Vulnerable Plaques
● Do vulnerable plaques manifest in a focal or diffuse manner within an
atherosclerotic coronary segment?
● How frequently do they occur compared to stable or hard plaques?
● How far in advance of clinical events do they appear?
● Do they herald plaque rupture or progression routinely or just occasionally?
● What is the probability of a vulnerable plaque becoming active in the future?
Over what time frame? Can they heal spontaneously without clinical
significance or events?uture depend on understanding the mechanisms of disease
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